TY - JOUR
T1 - Engineering a Humanised Niche to Support Human Haematopoiesis in Mice
T2 - Novel Opportunities in Modelling Cancer
AU - Sanchez-Herrero, Alvaro
AU - Calvo, Isabel A
AU - Flandes-Iparraguirre, Maria
AU - Landgraf, Marietta
AU - Lahr, Christoph A
AU - Shafiee, Abbas
AU - Granero-Molto, Froilán
AU - Saez, Borja
AU - Mazo, Manuel M
AU - Paiva, Bruno
AU - de Juan Pardo, Elena
AU - Nicol, Andrew
AU - Prosper, Felipe
AU - Bray, Laura J
AU - McGovern, Jacqui A
PY - 2020/8
Y1 - 2020/8
N2 - Despite the bone marrow microenvironment being widely recognised as a key player in cancer research, the current animal models that represent a human haematopoietic system lack the contribution of the humanised marrow microenvironment. Here we describe a murine model that relies on the combination of an orthotopic humanised tissue-engineered bone construct (ohTEBC) with patient-specific bone marrow (BM) cells to create a humanised bone marrow (hBM) niche capable of supporting the engraftment of human haematopoietic cells. Results showed that this model supports the engraftment of human CD34+ cells from a healthy BM with human haematopoietic cells migrating into the mouse BM, human BM compartment, spleen and peripheral blood. We compared these results with the engraftment capacity of human CD34+ cells obtained from patients with multiple myeloma (MM). We demonstrated that CD34+ cells derived from a diseased BM had a reduced engraftment potential compared to healthy patients and that a higher cell dose is required to achieve engraftment of human haematopoietic cells in peripheral blood. Finally, we observed that hematopoietic cells obtained from the mobilised peripheral blood of patients yields a higher number of CD34+, overcoming this problem. In conclusion, this humanised mouse model has potential as a unique and patient-specific pre-clinical platform for the study of tumour-microenvironment interactions, including human bone and haematopoietic cells, and could, in the future, serve as a drug testing platform.
AB - Despite the bone marrow microenvironment being widely recognised as a key player in cancer research, the current animal models that represent a human haematopoietic system lack the contribution of the humanised marrow microenvironment. Here we describe a murine model that relies on the combination of an orthotopic humanised tissue-engineered bone construct (ohTEBC) with patient-specific bone marrow (BM) cells to create a humanised bone marrow (hBM) niche capable of supporting the engraftment of human haematopoietic cells. Results showed that this model supports the engraftment of human CD34+ cells from a healthy BM with human haematopoietic cells migrating into the mouse BM, human BM compartment, spleen and peripheral blood. We compared these results with the engraftment capacity of human CD34+ cells obtained from patients with multiple myeloma (MM). We demonstrated that CD34+ cells derived from a diseased BM had a reduced engraftment potential compared to healthy patients and that a higher cell dose is required to achieve engraftment of human haematopoietic cells in peripheral blood. Finally, we observed that hematopoietic cells obtained from the mobilised peripheral blood of patients yields a higher number of CD34+, overcoming this problem. In conclusion, this humanised mouse model has potential as a unique and patient-specific pre-clinical platform for the study of tumour-microenvironment interactions, including human bone and haematopoietic cells, and could, in the future, serve as a drug testing platform.
UR - http://www.scopus.com/inward/record.url?scp=85089503598&partnerID=8YFLogxK
U2 - 10.3390/cancers12082205
DO - 10.3390/cancers12082205
M3 - Article
C2 - 32781703
SN - 2072-6694
VL - 12
SP - 1
EP - 23
JO - Cancers
JF - Cancers
IS - 8
M1 - 2205
ER -